Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
तुलना करने के लिए मीट्रिक्स | ORY | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधORYपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −47.8x | −2.8x | −0.5x | |
PEG अनुपात | 14.11 | −0.17 | 0.00 | |
क़ीमत/बुक | 2.0x | 1.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 23.8x | 4.5x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 66.1% | 106.1% | 54.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.1% | 8.5% | अनलॉक करें |